The document is an invitation and agenda for the "Partnerships for Drug Delivery Conference" taking place April 26-28, 2010 in Philadelphia, PA. It outlines the schedule of sessions and presentations focused on drug delivery partnerships, licensing opportunities, and innovations. Key details include: - Register by March 12, 2010 to receive up to $600 off registration fees. - Sessions will discuss identifying partnership opportunities, addressing patent strategies, leveraging alliance management, FDA approval processes, and case studies. - Presentations from major pharmaceutical companies like AstraZeneca, Merck, Pfizer, and Novo Nordisk. - Networking opportunities with industry professionals from areas like business development, licensing, and regulatory affairs

1. Register by March 12, 2010 and
Presents
receive up to $600 off! See page 8 for details.
Discover Strategic Innovations Within Licensing,
Patent Opportunities, Delivery Technologies and
Alliance Management
April 26-28, 2010 • Philadelphia, PA
Participating
Organizations Include:
Highlights of This Program Include: • GlaxoSmithKline
• Identifying successful factors and strategies for leveraging delivery • Pfizer, Inc.
partnerships • Merck & Co.
• Addressing patent opportunities in drug delivery concept • AstraZeneca
• Leveraging alliance management into partnerships • Sanofi Aventis US
• Using innovative drug delivery formulations to extend the product • Novo Nordisk
lifecycle
• Novartis
• Discussing the needs and relationships of specialty pharma companies • Boehringer-Ingelheim
with drug delivery companies
• Baxter Healthcare
• Improving bioavailability and superiority through advanced drug
delivery systems • Coviden
• Understanding the FDA requirements to streamline the process and • Purdue Pharma
obtain fast track approvals for drug delivery products • Arsenal Medical
Media Partners:
www.partnershipsdrugdelivery.com

2. April 26-28, 2010 • Philadelphia, PA
Dear Colleagues, Who will you meet at the
conference:
Drug delivery is an increasingly impo
rtant sector within the pharmaceutica
undergone rapid growth within the l industry, which has Vice Presidents, Directors, Associate
last few years. Drug delivery technolo
growth of pharmaceutical compani gies are driving Directors, Managers, Principals,
es and boosting their revenue by exten
profitable lifecycle through new form ding the product‘s Consultants, Business Leaders within:
ulations, combinations and reposition
ing.
This conference is designed to help Drug Delivery
pharmaceutical, biotechnology and
companies maximize deal making drug delivery Licensing
potentials and mitigate risks to achie
sustainability. It will provide real life ve long-term
considerations for deal-making and Business Development
technology application strategies in drug delivery
your organization.
Product Design
At this year’s Partnerships for Drug
Delivery Conference, you will hear Technology Assessment
and case study examples including 17+ in-depth sessions
:
•
Reviewing the outcome of pharma New Product Development
partnering across the industry over
•
Evaluating if licensing is a good optio the last 10 years
n for drug delivery partnerships
•
Understanding the FDA requirements Life Cycle / Portfolio Management
to streamline the process and obta
approvals for drug delivery products in fast track
Research & Development
•
Examining late stage successful and
unsuccessful diabetes licensing oppo
•
Novel drug delivery technologies and rtunities Strategic Alliances
therapeutics
•
Discussing the needs and relationsh
ips of specialty pharma companies Regulatory Affairs
companies with drug delivery
•
Integrating patent considerations
into a deal making process Manufacturing
Benefit from industry presentations
and perspectives shared by AstraZene
GlaxoSmithKline, Purdue Pharma, ca, Merck, Pfizer,
Coviden, Novartis, Baxter, Sanofi Aven
Boehringer-Ingelheim and many more tis, Novo Nordisk, Sponsorship and
pharmaceutical, biotech and CRO
industry experts.
Exhibition 0pportunities
This conference promises to be a netw
orking and discussion-filled event
ideas and solutions to help you prep leaving you with new Sponsorships and exhibits are excellent
are for your next partnership or allian
ce. opportunities for your company to
Join us in Philadelphia and learn from showcase its products and services to high-
the experts
on these vital strategies and technolo level, targeted decision-makers attending
gies!
the Partnerships for Drug Delivery
eractive Conference. Pharma IQ and IQPC help
P.S Highly int e pre- companies like yours achieve important
and informativ shops! sales, marketing and branding objectives by
Simon Curtis rk setting aside a limited number of event
Senior Conference Director, Phar conference wo details. sponsorships and exhibit spaces, all of
maceutical IQ
or
Pharma IQ, a division of IQPC
Simon.curtis@iqpc.com
See page 3 f which are tailored to assist your
organization in creating a platform to
maximize its exposure at the event.
For more information on sponsoring or
For Registration Information and to Download the Complete Brochure exhibiting at the Partnerships for Drug
Visit www.partnershipsdrugdelivery.com or Call 1-800-882-8684 Delivery Conference, please call Mario
Matulich at (212) 885-2719 or
sponsorship@iqpc.com.
2 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684

3. PRE-CONFERENCE
WORKSHOPS Monday, 2010
April 26,
9:00am – 12:00pm (Registration at 8:30am)
A Partnering with Venture Capitalists in the Declining Financial Market and Effective Partnering &
Licensing Strategies to Identify Innovative Technologies for Life-Cycle Extension
The American financial market has declined in past year. Fund raising and What Will Be Covered:
venture capitalism within drug delivery has never been more important and • Examining existing financing colorations and how to get ready for
challenging during these volatile market conditions. The most critical part wider global implications
of life-cycle management strategies is to identify and leverage advanced • Discussing what venture capital expects from investments
technologies. This workshop will guide you through the process of • Investigating how seed funding can be obtained through creative deal
searching for and working with the scientific society more effectively. structures
• Ascertaining effective partnering & licensing strategies to identify
How You Will Benefit: innovative technologies for life-cycle extension
• Learning how to raise funds in the global financial market
• Understanding how to convince venture capital to invest in your deals Workshop Leader:
• Identifying key areas for life-cycle management and pipeline extension Michael Lewis, Principal, Excend Consulting Group
• Understanding how licensing is playing a key role in life-cycle
management strategies
1:00pm – 4:00pm (Registration at 12:30pm – Lunch Included)
B Legal Considerations for “Non-Lawyers” to Maximize Deal Making Potential
Working with a legal team has been a headache for most business What Will Be Covered:
development professionals in drug delivery deals. Speaking the same • Providing an update on recent FDA legislation on drug delivery
language with the legal team and understanding their concerns are • Highlighting IP issues in drug delivery deals
becoming more important than ever to ensure that you control the risks • Utilizing global licensing strategies to acquire drug delivery technology
of the deals. • Discussing deal valuations from legal perspective
How You Will Benefit: Workshop Leader to be announced.Please check
• Understanding the legal framework of drug delivery technology www.partnershipsdrugdelivery.com for further details.
• Knowing how to work with the legal team to manage patent issues in
the deal making process
• Building an innovative deal structure to achieve life cycle management
CONFERENCE DAY ONE
Tuesday, April 27, 2010
7:30 Registration and Coffee of failed alliances
• The role of big pharma: Can pharma survive as a
8:30 Welcome Address and Chairperson’s Opening marketing vehicle rather than as an innovator?
Remarks • Understanding if mega-mergers drive profits or stifle innovation:
How can they be used as a tool for organic growth?
8:45 Opening Keynote Session: Evaluating the • Discussing novel approaches for the pharmaceutical industry to
Successes of Pharma Partnering: Reviewing the ensure success in the next decade within the delivery partnering
Outcome of Pharma Partnering Across the space
Industry over the Past 10 Years Mahesh Chaubal, PhD
• Determining if the current model will sustain or inhibit growth Director, Global R&D, Medication Delivery
in future Baxter Healthcare
• Identifying the successful partnerships and uncovering the cost
3 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684

4. DAY ONE Continued...
Effective Deal Management and Business Development Legal and Regulatory Perspectives
on Drug Delivery Partnerships
9:30 Panel Discussion: The Voice from Big Pharma: Discussing
Successful Factors and Strategies for Leveraging Drug 1:30 Successfully Acquiring a Biosimiliar in Drug
Delivery Partnerships Delivery for Partnering
• Providing advice on the decision making processes within large • Effectively tackling the approval process for biosimilars and
pharmaceutical and biotech corporations addressing the challenges posed by the sophisticated
• Exploring drivers and inhibitors in the deal making process for big pharma manufacturing processes of biologic drugs
companies • Successfully partnering an agreement to develop and
• Knowing what qualities to look for from your potential partnering commercialize a biosimiolar in development for the potential
organization
treatment of Gaucher’s disease
• Identifying when and how to approach the right people within your • Passing Phase III clinical studies, and is preparing to complete a
proposed partnering organization
rolling New Drug Application (NDA) with the U.S. Food and
• Understanding and overcoming the most common headaches of
Drug Administration (FDA)
partnerships
• Facilitating the development and expediting the review of drugs
Augustine Yee to treat rare conditions or diseases, as well as an Emergency
Senior Director, Global Strategic Planning and Business Development Use Authorization
AstraZeneca • Aiming to meet the needs of many patient populations, including
David Arvan those affected by rare diseases both domestically and internationally
Director, US Business Development
Christopher Slavinsky
AstraZeneca
Assistant General Council, Established Products Brand
Vijay Tammara Pfizer, Inc.
Senior Director, Regulatory Affairs
Merck & Co. 2:15 Panel Discussion: Addressing Patent
Opportunities in Drug Delivery Concept
10:15 Morning Networking Break • Specialty pharma, drug delivery, biotech and even generic companies
can all greatly benefit from careful and early strategic patent
11:00 Understanding if Licensing is a Good Choice For Drug planning concerning products they propose to bring to market
Delivery Partnerships • Recognizing that new drug development is a high risk venture
• Examining the impact to future collaborators, buyouts, or licensing
which takes a great deal of time, has an exceptionally low success
activities related to your project
rate, and in the case of a successful new drug development
• Discussing implications for manufacturing and scale-up activities
• Identifying which people should be responsible for the technology that is
• Examining important opportunities for patent protection that
licensed should not be (but often are) neglected by specialty pharma,
• Utilizing a contract manufacturing organization for your project impacting drug delivery and generic companies
the licensing of technology
• Establishing a successful patent lifecycle management team
• Analyzing who will own newly invented • Identifying the patent landscape
IP as the project scales-up • Beyond Big Pharma – Specialty Pharma, Branded and Non-
• Discussing whether licensing is going to make you more or less competitive Branded Generics
James Eshelby, PhD Balu Gupta
Director, Strategic Alliances Associate Vice President, Head, CNS Patent Operations
Pfizer, Inc. Sanofi-Aventis US
11:45 Panel Discussion: Leveraging Alliance Management into Wendy A. Petka, PhD, J.D.
Partnerships Director & Senior Counsel, Intellectual Property
• Leveraged alliance strategies to capitalize on technology and build Boehringer Ingelheim Corporation
promising drug pipelines Christopher Slavinsky
• Assigning responsibilities for alliance management within your own Assistant General Council, Established Products Brand
decision-making structure
Pfizer, Inc.
•
Cooperating with your drug delivery partners to avoid unanticipated
challenges
• Evaluating the mechanisms and business models to determine the deal
3:00 Understanding the FDA Requirements to
value in the current competitive market
Streamline the Process and Obtain Fast Track
Approvals for Drug Delivery Products
David H. Donabedian, PhD, MBA Innovative pharmaceutical companies are faced with
Vice President, Strategic Alliances, US CEEDD unprecedented challenges to get approvals from the FDA as the
GlaxoSmithKline regulations are significantly tightened.
PJ Anand • Thinking through the FDA perspective to achieve more with less
Executive Vice President, Corporate Development • Understanding the stages of regulatory approval
Arsenal Medical, Inc • Streamlining the filing processes with proven drug superiority
• Creating internal synergy to accelerate the process
Haro Hartounian, PhD
Chief Executive Officer Vijay Tammara
Vyteris Senior Director, Regulatory Affairs
Merck & Co.
12:30 Networking Luncheon
4 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684

5. DAY ONE Continued...
3:45 Afternoon Networking Break 5:15 Panel Discussion: What is
Restricting Big Pharma’s Involvement
Diabetes Therapeutic Licensing Opportunities with Licensing & Partnering within the
and Technology Assessment Diabetes Arena?
• Discussing the successes and failures of past pharma and
4:15 Examining Late Stage Successful and Potential Diabetes delivery technology collaborations within the diabetes space
Licensing Opportunities •
Identifying and forecasting successes of the future product
• Understanding future licensing opportunities within the diabetes and pipelines within a growing therapeutic area
metabolic space • Aligning your proposed partner’s aims and goals with your own
• Discussing what is required from smaller companies to promote their • Understanding the incentives for large companies to seek small
successful clinical phase work further specialized external sources
• Identifying successful investment opportunities within the diabetes licensing • Enhancing the likelihood of a successful scouting process
market • The visibility in the pharmaceutical arena
• Discussing future potential collaborative opportunities
Thomas Landh
Thomas Landh, Director, Strategy and Sourcing
Director, Strategy and Sourcing Novo Nordisk
Novo Nordisk
6:00 Chairperson’s Closing Remarks and
4:45 Technical Session: Updates within Novel Diabetes Drug End of Day One
Delivery Technology
This session will give three biotech companies who specialize within the
diabetes drug delivery technology space the opportunity to deliver a 10
minute presentation showcasing their novel delivery technology to our
audience of potential partners and investors. This is a must attend for Pharma,
biotech and the investment community. Presentation areas will include:
• Late stage rapid acting injectable insulin
• Ultra rapid injectable insulin
• Clinical phase transdermal basal insulin
Contact Simon Curtis at simon.curtis@iqpc.com
for presentation opportunities
CONFERENCE DAY TWO
Wednesday, April 28, 2010
8:00 Registration and Coffee 9:30 The Use of Modified Formulation and
Delivery Technologies to Repurpose Old Drugs
8:30 Welcome Address and Chairperson’s Opening • Gaining a current and focused overview of formulation
Remarks technologies in the drug industry
• Assessing and forecasting the future of innovation in the drug
Maximizing Product Exposure formulations arena
within the Marketplace • Understand the issues faced in aligning drug formulation with
drug-delivery
8:45 Novel Delivery Technologies & Therapeutics • Improve the efficacy of chemical entities and deliver the desired
•
Using technology to deliver patient centric and personalized therapeutic effect of drugs, both novel and established
therapeutic solutions • Addressing formulation issues which occur within the CNS arena
•
Evaluation of new modalities to enable data driven investments • Discussing advancements in technology, formulations being
in technology developed enabling and benefiting technology transfer
•
Early integration of technology to maximize
Balu Gupta
the potential of and differentiation of products.
Associate Vice President, Head, CNS Patent Operations
•
Building a portfolio of technologies that can be ‘plugged in‘ as
Sanofi-Aventis US
needed.
Saran Kumar, PhD
David Roberts
Principal Fellow, Pharmaceutical & Analytical Development
Director, External Business Operations Technical R&D
Novartis Pharmaceuticals Corporation
Novartis Institutes for BioMedical Research, Inc.
Vijay Tammara
Senior Director, Regulatory Affairs
Merck & Co.
5 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684

6. DAY TWO Continued...
10:15 Morning Networking Break Forming an Effective Alliance
11:00 Improving Bioavailability and Superiority 2:15 Discussing the Needs and Relationships of
through Advanced Drug Delivery Systems Specialty Pharma Companies with Drug Delivery
• Alterations in drug delivery produce substantial changes in the Companies
bioavailability which may lead to significant improvement on • Examining the relationships between specialty pharma and drug
efficacy and tolerability delivery technology companies
• Leveraging advanced drug delivery systems to consistently • How specialty pharma creates and evaluates new product opportunities
enhance patient compliance and overall drug effect is crucial for • Debating whether specialty pharma is the future for Drug
product enhancement strategies Delivery technology companies
• Examining the recent advancement of drug delivery systems
Allen G. Downs
• Analyzing the impact of drug delivery systems on bioavailability
Senior Executive, Director, Licensing & Business Development
• Sustaining product value and combating generics by launching
Purdue Pharma L.P.
the improved or next-generation
Saran Kumar, PhD 3:00 Afternoon Networking Break
Principal Fellow, Pharmaceutical & Analytical Development
Novartis 3:30 Discussing the Strategic Benefits of Merging
Two Commercial Pipelines and Putting in Place
11:45 Developing a Novel Active Transdermal Delivery Plans for Effective Integration
System for Small Molecules and Peptides • Avoiding the main problems and issues with merging
• Developed a proprietary active patch technology based on the commercial pipelines
principle of iontophoresis • Discussing key points in technology transaction negotiation
• Consisting of a miniaturized pre-programmed controller and a • Assisting technology transfer to your organization
ready-to-use pre-filled patch • Uncovering examples of successful integration of commercial pipelines
• Examining a novel technology in it’s ability to control the flux of • Identifying approaches for shortening extremely long product
drug through the skin by application of small and precisely development cycles
controlled electrical current • Evaluating shorter testing cycles and getting faster approvals for
• Discussing numerous preclinical and clinical studies for peptides new compound entities (NCEs)
and small molecules to demonstrate the safety and efficacy
Mahesh Chaubal, PhD
• Displaying completed Phase II clinical evaluation of the safety
Director, Global R&D, Medication Delivery
and efficacy of several dosage strengths
Baxter Healthcare
Haro Hartounian, PhD
Chief Executive Officer 4:15 Integrating Patent Considerations into a Deal
Vyteris Making Process
• Confirming patentability of the potential drug delivery technology
12:30 Networking Luncheon and the patent protection scope of this new technology
•
Defining patent inventorship such as employee inventions,
1:30 Innovations in Modified Release Systems university collaborative research agreements and joint inventions
• Developing products and formulation expertise for delayed • Conducting Freedom-To-Operate (FTO) to minimize the risks of
release and extended/controlled release applications patent infringement
• Supporting the demand of today’s pharmaceutical industry with
Wendy A. Petka, PhD, J.D.
oral modified release dosage forms
Director & Senior Counsel, Intellectual Property
• Improving patient compliance through dosage frequency alteration
Boehringer-Ingelheim Corporation
• Leveraging novel drug delivery technologies
• Case Study: Timed release oral drug delivery system Allen G. Downs
Senior Executive, Director, Licensing & Business Development
Vishal K. Gupta, MBA, PhD
Purdue Pharma L.P.
Director, Pharmaceutical R&D
Covidien
5:00 Chairperson’s Closing Remarks and Close of
Conference
6 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684

7. ABOUT OUR PARTNERS
Drug Delivery Technology
Website: www.drugdeliverytech.com
Drug Delivery Technology publishes scientific articles, special features, and market news covering the science
and business of drug delivery, formulation development, product life-cycle management, technology
assessment, product development, contracting and licensing.
Specialty Pharma is a self-contained featured section inside Drug Delivery Technology addressing the business
strategies behind portfolio optimization, pipeline management, and partnering with contract service providers
throughout the drug development process.
Drug Delivery Technology is committed to advancing the science, technology, and business of pharmaceutical
and biological delivery systems
PharmaVOICE
Website: www.pharmavoice.com
PharmaVOICE magazine, reaching more than 17,500 U.S.-based life-sciences executives, is the forum that
allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry.
PharmaVOICE, and its supporting VIEW publications, provide readers with insightful and thought-provoking
commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues
from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and
information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts,
Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com provides a
comprehensive directory of products, services, and solutions for the life-sciences industry. To Raise Your VOICE,
contact feedback@pharmavoice.com
PharmCast
Website: www.PharmCast.com
www.PharmCast.com is the world leading website designed specifically for pharmaceutical, clinical and
biotechnology professionals. www.PharmCast.com brings up-to-date information on pharmaceutical patents,
FDA, news, jobs and Buyer's Guide to our visitors. It was created and is maintained by pharmaceutical and
biotechnology professionals. Visit www.PharmCast.com and discover for yourself why it is so popular among
professionals.
Pharmaceutical Manufacturing
Website: www.pharmamanufacturing.com
Pharmaceutical Manufacturing is devoted exclusively to drug manufacturing and scale-up and dedicated to
sharing best practices that will help drug industry professionals improve product quality, ensure compliance,
reduce cycle times, eliminate organizational and information silos and reduce time to market for new drugs,
drugs that can actually be manufactured.
CanBiotech
Website: www.canbiotech.com
CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The
Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture
capital directories and databases. Publications include the Bio Outsourcing Asia© Publication. Read about
opportunities in India, China, Malaysia, Singapore, Taiwan and more. www.canbiotech.com
7 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684

8. Discover Strategic Innovations Within Licensing,
Patent Opportunities, Delivery Technologies and
Alliance Management
April 26-28, 2010 • Philadelphia, PA
5 EASY WAYS TO
REGISTER:
1 Web: www.partnershipsdrugdelivery.com
2 Call: 1-800-882-8684
3 Email: info@iqpc.com
(Email this form to info@iqpc.com or fax to 646-378-6025) 4 Fax: 1-646-378-6025
5 Mail: IQPC -535 5th Avenue, 8th Floor,
YES! Please register me New York, NY 10017
❑ Conference Only ❑ Conference + 1 Workshop ❑ A or ❑ B ❑ All Access
Name ____________________________________________________________ Job Title _________________________________________________
Organization______________________________________________________ Approving Manager________________________________________
Address _____________________________________________ City________________________________________State__________Zip_________
Phone________________________________________________ E-mail_______________________________________________________________
❑ Please keep me informed via email about this and other related events.
❑ Check enclosed for $_________ (Payable to IQPC) ❑ Charge my ❑ Amex ❑ Visa ❑Mastercard ❑ Diners Club
Card #______________________________Exp. Date____/____ CVM Code______
❑ I cannot attend, but please keep me informed of all future events. 16631.002/D/SC
Registration Information Team Discounts: For information on team discounts, please
contact IQPC Customer Service at 1-800-882-8684. Only one
discount may be applied per registrant.
Register and Pay Register and Pay Standard
by March 12, 2010 by April 9, 2010 Price Details for making payment via EFT or wire transfer:
JPMorgan Chase - Penton Learning Systems LLC dba
Conference Only $1,199 $1,599 $1,799 IQPC: 957-097239 ABA/Routing #: 021000021
Save $600 Save $200 Reference: Please include the name of the attendee(s) and the
event number: 16631.002
All Access $2,199 $2,599 $2,799 Payment Policy: Payment is due in full at the time of registration
Save $698 Save $298 Save $98 and includes lunches and refreshment. Your registration will not
be confirmed until payment is received and may be subject to
Workshops $549 each $549 each $549 each cancellation.
For IQPC’s Cancellation, Postponement and Substitution
Policy, please visit www.iqpc.com/cancellation
A $99 processing charge will be assessed to all registrations not accompanied by credit card payment at the
time of registration. ©2010 IQPC. All Rights Reserved. The format, design, content
and arrangement of this brochure constitute a trademark of IQPC.
MAKE CHECKS PAYABLE IN U.S. DOLLARS TO: IQPC Unauthorized reproduction will be actionable under the Lanham
* CT residents or people employed in the state of CT must add 6% sales tax. Act and common law principles.
8 Register Online at www.partnershipsdrugdelivery.com or Call 1-800-882-8684